Cellectis Stock (NASDAQ:CLLS)
Previous Close
$1.80
52W Range
$1.75 - $3.77
50D Avg
$2.10
200D Avg
$2.42
Market Cap
$126.88M
Avg Vol (3M)
$34.62K
Beta
3.23
Div Yield
-
CLLS Company Profile
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
CLLS Performance
Peer Comparison
Ticker | Company |
---|---|
SLNO | Soleno Therapeutics, Inc. |
NRIX | Nurix Therapeutics, Inc. |
CYT | Cyteir Therapeutics, Inc. |
KYMR | Kymera Therapeutics, Inc. |
FHTX | Foghorn Therapeutics Inc. |
INBX | Inhibrx Biosciences, Inc. |
RGNX | REGENXBIO Inc. |
LIAN | LianBio |
ERYP | PHAXIAM Therapeutics S.A. |
SGTX | Sigilon Therapeutics, Inc. |
PASG | Passage Bio, Inc. |
IPHA | Innate Pharma S.A. |
HCWB | HCW Biologics Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
DMAC | DiaMedica Therapeutics Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
GNFT | Genfit S.A. |
KZR | Kezar Life Sciences, Inc. |
STTK | Shattuck Labs, Inc. |
ELYM | Eliem Therapeutics, Inc. |